Interleukin-17A Antagonist
9 drugs across 2 manufacturers|0 Generic,9 Brand
The Interleukin-17A Antagonist class contains 9 NDCs from 2 manufacturers (0 generic, 9 brand), at an average NADAC of $6376.01 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
9
0G / 9B
Manufacturers
2
Avg $6376.0118/unit
Avg 7d Change
-0.15%
Across 3 drugs with changes
7d Activity
of 9 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Frequently Asked Questions
How many drugs are in the Interleukin-17A Antagonist class?
The Interleukin-17A Antagonist class contains 9 NDCs from 2 manufacturers — 0 generic and 9 brand products.
What is the average price of Interleukin-17A Antagonist drugs?
The average NADAC for the Interleukin-17A Antagonist class is $6376.0118 per unit across 9 NDCs.
Which manufacturers make Interleukin-17A Antagonist drugs?
2 manufacturers make drugs in the Interleukin-17A Antagonist class. Ranked by number of NDCs, the largest are Novartis Pharmaceuticals Corporation (5), Eli Lilly and Company (4).
How has Interleukin-17A Antagonist pricing changed recently?
Over the past 7 days, 1 NDC in this class rose and 2 fell, with a class-wide average change of -0.1%.
Manufacturer Breakdown
2 manufacturers producing drugs in this therapeutic class
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
COSENTYX 150 MG/ML SYRINGE secukinumab | $7923.3134 per ML | — |
COSENTYX SENSOREADY 150 MG/ML PEN secukinumab | $7869.8320 per ML | — |
TALTZ 80 MG/ML AUTOINJECTOR (2-PACK) ixekizumab | $7435.8708 per ML | — |
TALTZ 80 MG/ML SYRINGE ixekizumab | $7402.0679 per ML | — |
TALTZ 80 MG/ML AUTOINJECTOR (3-PACK) ixekizumab | $7371.1393 per ML | — |
TALTZ 80 MG/ML AUTOINJECTOR ixekizumab | $7369.2696 per ML | +0.05% |
COSENTYX UNOREADY 300 MG/2 ML PEN (1 PEN) secukinumab | $4085.7198 per ML | -0.11% |
COSENTYX (150 MG/ML) 300 MG DOSE-2 SYRINGES secukinumab | $3965.6440 per ML | — |
COSENTYX SENSOREADY 300 MG DOSE/2 PENS (150 MG/PEN) secukinumab | $3961.2495 per ML | -0.39% |